Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 32 Carcinoma, Non-Small-Cell Lung 30 Neoplasms 10 Neoplasm Metastasis 9 Lung Neoplasms 9 Adenocarcinoma 9 Colorectal Neoplasms 8 Esophageal Neoplasms 7 Carcinoma, Hepatocellular 7 Colonic Neoplasms 5 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Rectal Neoplasms 3 Melanoma 3 Liver Neoplasms 3 Carcinoma, Transitional Cell 3 Biliary Tract Neoplasms 3 Ureteral Neoplasms 2 Thymoma 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Non-small Cell Lung Cancer Metastatic 2 Malignant Solid Tumor 2

Interventions

Cisplatin 46 Carboplatin 43 pembrolizumab 39 Paclitaxel 38 Gemcitabine 27 Radiotherapy 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 18 Radiotherapy, Intensity-Modulated 17 Docetaxel 17 Specimen Handling 15 Nivolumab 15 Cetuximab 15 Cyclophosphamide 14 durvalumab 13 Fluorouracil 13 130-nm albumin-bound paclitaxel 10 Platinum 9 Bevacizumab 9 osimertinib 8 Sunitinib 8 Sorafenib 8 Radiation 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Capecitabine 8 1,2-diaminocyclohexaneplatinum II citrate 8 Ipilimumab 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡